Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Vitamin K antagonists in children with heart disease: height and VKORC1 genotype are the main determinants of the warfarin dose requirement.

Blood - 19 Jan 2012

Moreau Caroline, Bajolle Fanny, Siguret Virginie, Lasne Dominique, Golmard Jean-Louis, Elie Caroline, Beaune Philippe, Cheurfi Radhia, Bonnet Damien, Loriot Marie-Anne

Abstract excerpt

Managing vitamin K antagonist (VKA) therapy is challenging in children because of a narrow therapeutic range and wide inter- and intra-individual variability in dose response. Only a few small studies have investigated the effect of nongenetic and genetic factors on the dose response to VKAs in children. In a cohort study including 118 children (median age 9 years; range, 3 months-18 years) mostly with cardiac...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Body Height
Share to Cytochrome P-450 CYP2C9

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cytochrome P450 Family 4

Share to Heart Diseases

Share to International Normalized Ratio

Share to Vitamin K

Share to Vitamin K Epoxide Reductases

Share to Warfarin

Source

Open in PubMed Open full text

Identifiers

PMID: 22130800
DOI: 10.1182/blood-2011-07-365502
PMCID: PMC3384479

Genes

VKORC1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Vitamin K antagonists in children with heart disease: height and VKORC1 genotype are the main determinants of the warfarin dose requirement.PMID 22130800Read ↗

VKORC1 and CYP2C9 genotype and patient characteristics explain a large proportion of the variability in warfarin dose requirement among children.Semantic proximity Read ↗

Genetic and clinical determinants influencing warfarin dosing in children with heart disease.Semantic proximity Read ↗

Characterizing variability in warfarin dose requirements in children using modelling and simulation.Semantic proximity Read ↗

In pediatric patients, age has more impact on dosing of vitamin K antagonists than VKORC1 or CYP2C9 genotypes.Semantic proximity Read ↗

Effect of CYP2C9, VKORC1, and CYP4F2 polymorphisms on warfarin maintenance dose in children aged less than 18 years: a protocol for systematic review and meta-analysis.Semantic proximity Read ↗

The effect of CYP2C9 and VKORC1 genetic polymorphisms on warfarin dose requirements in a pediatric population.Semantic proximity Read ↗

The impact of age and CYP2C9 and VKORC1 variants on stable warfarin dose in the paediatric population.Semantic proximity Read ↗

Frequency of CYP2C9 and VKORC1 gene polymorphisms and their influence on warfarin dose in Egyptian pediatric patients.Semantic proximity Read ↗

The pediatric acenocoumarol dosing algorithm: the Children Anticoagulation and Pharmacogenetics Study.Semantic proximity Read ↗

CYP2C9, VKORC1, and CYP4F2 polymorphisms and pediatric warfarin maintenance dose: a systematic review and meta-analysis.Semantic proximity Read ↗

Effect of VKORC1, CYP2C9, CFP4F2, and GGCX Gene Polymorphisms on Warfarin Dose in Japanese Pediatric Patients.Semantic proximity Read ↗

VKORC1 and CYP2C9 genotypes are predictors of warfarin-related outcomes in children.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.